CERO THERAPEUTICS HOLDINGS I (CERO) Stock Price, Quote, News and Summary
NASDAQ:CERO - Nasdaq - US71902K1051 - Common Stock
CERO Quote and Key Statistics
CERO THERAPEUTICS HOLDINGS I
NASDAQ:CERO (1/17/2025, 8:00:00 PM)
After market: 2.44 +0.1 (+4.27%)2.34
-0.15 (-6.02%)
CERO Financial Highlights
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -29.63% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
CERO Performance and Technical Analysis
CERO Ownership and Analysts
CERO Latest News and Analysis
Top movers in Wednesday's session
Stay up-to-date with the latest market trends one hour before the close of the markets on Wednesday. Explore the top gainers and losers during today's session in our detailed report.
Let's take a look at the stocks that are in motion in today's session.
What's going on in today's session
The market is filled with gapping stocks in Wednesday's session. Let's discover which stocks are showing gap-ups and gap-downs.
Let's delve into the US markets on Wednesday and uncover the stocks that are experiencing notable gaps in today's session. Below, you'll find the gap up and gap down stocks.
Curious about what's happening in today's session? Check out the latest stock movements and price changes.
Here are the top movers in Tuesday's session, showcasing the stocks with significant price changes.
CERo Therapeutics Holdings, Inc. Announces Reverse Stock Split
About CERO
Company Profile
CERo Therapeutics Holdings, Inc. is a blank check company, formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The company is headquartered in South San Francisco, California and currently employs 8 full-time employees. The company went IPO on 2021-10-06. The Company’s proprietary approach to T cell engineering, enables it to integrate certain desirable characteristics of both innate and adaptive immunity into a single therapeutic construct, which is designed to engage the body’s full immune repertoire to achieve optimized cancer therapy. Its cellular immunotherapy platform is focused on redirecting patient-derived T cells to eliminate tumors by building in engulfment pathways that employ phagocytic mechanisms to destroy cancer cells, creating CERo, which is referred to as chimeric engulfment receptor t cells (CER-T). The firm is initiating clinical trials for its lead product candidate, CER-1236, for hematological malignancies.
Company Info
CERO THERAPEUTICS HOLDINGS I
201 Haskins Way, Suite 230
South San Francisco CALIFORNIA US
Employees: 8
Company Website: https://www.phoenixbiotechacquisitioncorp.com/
Phone: 6504072376
CERO Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 15.96 | 303.17B | ||
| AMGN | AMGEN INC | 14.16 | 146.27B | ||
| GILD | GILEAD SCIENCES INC | 20.73 | 114.46B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 827.45 | 108.68B | ||
| REGN | REGENERON PHARMACEUTICALS | 15 | 74.90B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.30B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 31.76B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.97B | ||
| ONC | BEIGENE LTD-ADR | N/A | 22.37B | ||
| NTRA | NATERA INC | N/A | 20.91B | ||
| BIIB | BIOGEN INC | 8.61 | 20.48B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.76 | 16.02B |